Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…
LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…
MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS
Rheumatologists can gain insight into patients’ state of health by watching them walk
How method of diagnosing, treating this inflammatory back disease characterized by stiffness and the presence of HLA-B27 gene has evolved
Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored
The Foundation names winners of education and training awards, career development research awards, and disease-targeted research grants
More finely tuned view of ankylosing spondylitis leads to better treatment, expert says
The 2011 ACR/ARHP Annual Meeting program offers a plethora of opportunities for health professionals to gain insight into emerging concepts in the diagnosis and treatment of rheumatologic disorders as well as improving quality of life in affected patients.
Condition often confused with other disorders